The field of clinical trials and therapeutics in Alzheimer disease (AD) is little more than 20 years old. Considerable progress has been made in crafting appropriate designs for clinical trials of promising therapeutic agents for AD. This article reviews basic issues in diagnostic criteria, choice of outcome measures, duration of trials and analytic strategies. Through trial and error, a general set of strategies has evolved for the assessment of putative therapies for mild to moderate AD. The experience of the past 2 decades has set the stage for discovering the next generation of anti-AD drugs and introducing those therapies at milder stages of the disease.
T herapeutics in Alzheimer disease (AD) has entered only its third decade. Before 1986, the methodology for conducting clinical trials in AD was virtually nonexistent. As a consequence of investigations with the cholinesterase inhibitor, tacrine, a conceptual framework for AD clinical trials quickly gelled. Guidelines were established by the US Food and Drug Administration (FDA) in 1990 that defined the general form of outcome measures. 1 The guidelines stipulated that a successful anti-AD drug would have to show benefits on both a cognitive test that reflected the core deficits in AD and a clinician's global impression. What was remarkable about the guidelines was that they did not specify an effect size, minimum or maximum trial duration nor any kind of risk:benefit algorithm. Over the 1990s, an informal consensus appeared that a trial of 6 months duration with about 100 to 120 subjects per treatment arm was sufficient. Currently, there are 4 drugs that are approved and marketed in the United States for the treatment of mild to moderate AD. (A fifth drug, tacrine, was also approved but is not marketed due to its hepatic and gastrointestinal toxicity.) These 5 drugs were approved based on the 1990 FDA guidelines. Several other compounds also underwent phase 3 trials but failed to show efficacy.
Although there is a growing recognition in the field that treatment at an earlier stage might be more effective, it is patients with mild to moderate disease that, by far, form the majority who present to physicians for treatment of dementia symptoms. Giving them the best possible therapy must still be a major goal for the field. The purpose of this review is to highlight some of the key neurocognitive issues in the design of clinical trials in mild to moderate AD.
DIAGNOSTIC CRITERIA
At the time when multicenter clinical trials were first initiated in AD, the NINCDS-ADRDA criteria 2 -had been accepted by the AD researchers worldwide. The AD criteria are usually used in tandem with the modified Hachinski Ischemic Index to reduce the probability of including patients with significant cerebrovascular disease. 3, 4 Mild to moderate severity of dementia was defined by a range of scores on the Mini-Mental State Examination (MMSE). 5 Although this approach is not beyond criticism, experience suggests very broad acceptance in the context of clinical trials.
TRIAL DESIGN AND DURATION
The randomized, double-blind, placebo-controlled, parallel-group design is the approach of choice for anti-AD drugs for mild to moderate AD. Alternative approaches such as cross-over designs are inadequate. The inevitable decline that occurs in AD violates a key assumption of the cross-over design, namely that patients are identical at the beginning of both phases. Studies that use a time-to-reach end point (survival) design are feasible, and have been carried out, for example, with vitamin E 6 and donepezil, 7, 8 but the majority of trials in mild to moderate AD have used end-of-trial evaluations as the primary outcome measures. The instruments for assessing cognition, function, and behavior are the focus of this review.
The initial multicenter trial of a cholinesterase inhibitor was only 6 weeks long. 9 In retrospect, it seems quite naive to think that a drug could change cognition in AD in such a short time frame. Because it became clear that in-study placebo effects could take 6 weeks or longer to dissipate, 10,11 longer trials were needed. For no empiric reason, the pivotal trials for all of the cholinesterase inhibitors were 5 to 6 months in duration. [10] [11] [12] [13] [14] [15] [16] [17] [18] Subsequently, 12 to 18 months of duration trials have become the preferred approach for mild to moderate AD, for example. [19] [20] [21] 
COGNITIVE OUTCOME MEASURES
In keeping with the FDA requirement that one of the primary outcome measures be able to ''detect changes in the core cognitive manifestations of dementia,'' 1 the cognitive instrument that has been used in all of the cholinesterase inhibitor trials and many subsequent trials was the AD assessment scale-cognitive (ADAScog). 22 Developed specifically for clinical trials in AD, the ADAScog yields a single score that reflects the arbitrary weighting of performance in several cognitive domains. In keeping with the focus on AD, the ADAScog gives much greater weight to performance on learning and memory than to other domains. It also covers the domains of language and spatial cognition, but does not address executive function. Because of the lack of coverage of executive functions, additional items have been added to the ADAScog such as number cancellation and mazes. 23 The standard method of analyzing ADAScog data in current clinical trials of mild to moderate AD is to use some form of linear regression such as analysis of variance or analysis of covariance in an intention-to-treat approach. Patients are included in analyses if they complete the trial or have at least 1 postrandomization ADAScog assessment. Covariates such as age, sex, or other variables prospectively identified as relevant such as baseline MMSE scores may be included.
The properties of the ADAScog are well understood. There is a curvilinear relationship between disease severity and rate of change on the ADAScog. In mild patients (eg, patients with MMSE scores in the 20 to 26 range at baseline), the rate of change is less than in the moderate range. 24 Patients with MMSE scores in the range of 14 to 21 generally show the greatest amount of change. With advancing severity of dementia such as in patients with MMSE scores less than 14, the rate of change in the ADAScog then tends to decrease because performance approaches ''floor'' levels on several items.
The variability in the ADAScog's change score has generally been equivalent to, or somewhat larger than, the amount of annual decline. For example, in an Alzheimer's Disease Cooperative Study trial of 2 nonsteroidal antiinflammatory drugs in mild to moderate AD (baseline MMSE scores between 13 and 26), 20 the placebo group declined 5.7 ± 8.2 points over 1 year. In an industry trial of rofecoxib, the annual decline of a nearly identical group of mild to moderate AD patients (baseline MMSE 14 to 26) 25 was 5.44 (standard deviation not given in publication). In contrast, in the AN-1792 immunization study in which only mild AD patients (MMSE 21 to 26) participated, the mean 1 year decline in the placebo group on the ADAScog was 0.6 ± 4.3 points. The very small annual change on the ADAScog in mild patients raises questions about the utility of the ADAScog at the mild end of the AD spectrum. Indeed, more sensitive cognitive test batteries have been proposed, 26 and one was used in the clinical trial of AN-1792. 27 It consists of 9 widely used neuropsychologic tests including subtests of the Wechsler Memory Scale, the Rey Auditory Verbal Learning Test, the Controlled Oral Word Association test, and Category fluency. 26 The neuropsychologic battery was evaluated by creating a z-score composite of all of the elements of the battery. That z-score composite declined 0.21 ± 0.42 points, which represented a much more favorable change to variance ratio than the ADAScog. 26 Because statistical power to detect treatment effects is a function of the size of the drug-versus-placebo difference and the inverse of the between-subjects variability, fewer subjects would be needed to insure adequate power to detect a drug effect on this neuropsychologic battery than the ADAScog.
The ratio of annual rate of change on the ADAScog and its variance are among the key elements that go into the possible sample size Â study duration configurations of a clinical trial. The initial severity level of patients also influences the amount of annual change to be expected on the ADAScog in the control group. Longer duration trials will result in greater decline in the placebo group, with about the same level of variability between subjects. Hence sample sizes could be smaller in longer duration trials. However, attrition will be greater with longer studies, particularly if more moderately affected patients are enrolled. Thus, although effect sizes in longer trials imply the need for fewer subjects, greater attrition will require enrolling more subjects.
The ADAScog has proved to be a valuable tool because the 5 approved drugs exhibited treatment effects with it. The effect size in the cholinesterase inhibitor trials has been about 3 to 4 points on the ADAScog over 6 months 10-13 compared with the yearly decline in the ADAScog of about 6 points, for example Refs.20,25, thus making the effect size equivalent to a delay in decline of about 6 to 8 months. Until there is more experience with alternatives, the ADAScog will probably remain as the cognitive instrument of choice for AD clinical trials for the immediate future. One persistent question about the ADAScog has been in defining what amount of therapeutic difference is clinically meaningful.
The ADAScog as a clinically relevant outcome in AD trials is not without its detractors; some critics of currently approved AD drugs would claim that the ADAScog is too sensitive to change in that the ''statistically significant'' changes observed in the trials of the approved drugs have not been clinically relevant. Because the cholinesterase inhibitors and memantine are palliative therapies whose impact is clearly modest in the majority of patients, the critics are really directing their skepticism at the drugs, not the ADAScog.
CLINICIAN'S GLOBAL IMPRESSION RATINGS
The other primary outcome measure specifically mentioned in the FDA guidelines 1 was a clinician's global assessment. The form of a global assessment was not specifically defined, but rather the guideline required a tool that was meant to identify clinically meaningful change (''clinical utility'') 1 over the course of the clinical trial, from the perspective of a skilled clinician that was separate from cognitive tests. Clinical meaningfulness was not defined by the FDA draft guideline, but the assumption of the regulatory agency was that clinicians ''would know it when they see it.'' The original FDA guideline envisioned the use of a 7-point scale for the clinician's global rating, with a rating of ''1'' indicating marked improvement, ''4'' indicating no change, and ''7'' indicating severe decline. The judgment as to whether the patient was worse, unchanged, or better would be made by a clinician who was blinded to the scores from the cognitive tests of the primary outcome measure, but the judgment would, of necessity, include information from the clinician's own mental status examinations. Furthermore, the clinician involved in the global assessment was to be kept unaware, to the extent possible, of any adverse events that might unblind the treatment assignment. Initially, the FDA wished that only a patient examination be used for the determination, but ongoing discussions and dialogs made it clear that experts in the field felt that input from a primary caregiver was essential. A clinician's global impression then became a complex judgment involving evaluating evidence from 2 sources-the patient and the informant-and then assigning a rating to the overall impression of change. 28 Global change ratings have been routinely evaluated by intention to treat procedures and nonparametric statistics such as Cochran-Mantel-Haenszel w 2 test.
Because the FDA did not otherwise specify the structure and procedure for carrying out a valid assessment of change, industry and academic trialists experimented at first with several different versions. Although there may not be universal agreement on 1 version, the procedures and interview structure laid out by the Alzheimer's Disease Cooperative Study Clinical Global Impression of Change (CGIC) represent a validated and straightforward structured approach to the clinician's global impressions that preserves the original intent of the FDA guidelines. 29 It uses information from both the patient and the caregiver.
Another approach to global ratings has been to use the Clinical Dementia Rating (CDR) Scale. 30 Its administration is somewhat different than a typical clinical global impression because the CDR is semistructured and includes 6 individual domains of cognition and function. A severity score of 0 (normal) to 3 (severe impairment) is given for each domain. In addition, the CDR is scored both at baseline and follow-up, whereas the clinician's global impression is completed only at follow-up. Usually, the scores of the 6 domains are added together to yield a ''sum of boxes'' overall score. However, both the CDR and the clinician's global impression can be used to fulfill the spirit of the FDA requirement for the opinion of a skilled clinician who has weighed all relevant information from both informants and patients them-selves. There is some empiric work on the properties of clinician's global impressions. 28, 29 Generally, these instruments are reliable, but they have greater test-retest variability than cognitive tests. In contrast to the ADAScog, global impressions are insensitive to small amounts of change.
Clinician's global impressions have also been successful in trials of cholinesterase inhibitors and memantine. Thus, despite the potential drawbacks and inefficiencies of clinician's global impressions, some anti-AD drugs have been capable of generating a drug-placebo difference on the measure.
One of the criticisms of the clinician's global assessment is that it is too insensitive. At the individual patient level, although the ADAScog score can vary from 0 to 70, and the CDR sum of boxes can vary from 0 to 18 in 0.5 increments, the CGIC can move only 0 to 3 points better or 0 to 3 points worse. At the level of analysis by group, however, insensitivity is less of an issue. In the placebo group of the pivotal 24-week donepezil trial, 11 the clinician's global impression declined 0.51 ± 1.0 rating points and the CDR sum of boxes declined 0.58 ± 1.73. The insensitivity may arise both from its moderate reliability and the coarseness of the rating scales. However, the feature of insensitivity is precisely what the FDA guideline intended for the instrument in order to detect only treatment effects that were visible to clinicians.
FUNCTIONAL ASSESSMENTS
Although the FDA guideline did not require assessments of daily functioning, most clinical trials have included some instrument that assessed caregiver opinions about the patients' daily functioning. Several instruments [31] [32] [33] and others have been devised for this purpose, but none of the instrument has emerged as the preferred one. There is of course much overlap between various instruments, but the lack of uniformity across trials has made it difficult to draw any conclusions about the magnitude of change demonstrable by functional assessments. In addition, the amount of change on a functional instrument that constitutes a clinically meaningful minimum is not established. In contrast to the ADAScog that often shows improvements in the placebo group in the first 6 weeks of study participation, functional assessments generally do not show improvement. An example of this phenomenon was illustrated in a trial of rivastigmine. 13 It appears that patients are not ''allowed'' to resume activities that they had previously given up.
Among the many concerns about measuring daily functioning is the wide variation in what prospective clinical trial participants ordinarily do. There are vast sex differences, differences depending upon whether a spouse is present or not, and vast differences in premorbid interests and abilities. Moreover, the informant who actually provides the information about daily functioning is another source of heterogeneity. Not only might perceptions of daily functioning on the part of the patient be colored by the informant's mood, abilities, and expectations, large differences might be expected between how adult children and spouses perceive a patient's functioning.
Whether daily functioning is measured with a specific functional assessment tool or whether it is evaluated in the context of a global impression, it is highly desirable for a drug that shows benefits on cognition to show drug benefits on function. Although it has not been possible to define a magnitude of benefit on functional measures that is clinically meaningful, a statistically significant result on a functional measure in a trial powered for an ADAScog drug effect would be encouraging.
One approach to the problem of measuring such a diverse construct like daily functioning has been to attempt to define an amount of clinically meaningful change prospectively for each patient, 34 and then use that definition to define an end point in a ''survival'' analysis. Such a strategy was successfully used with donepezil 7 and galantamine. 34 Although this is a particularly clever and efficient approach, others have felt that the methodology for defining individual treatment failure is not sufficiently reproducible to allow it to be used as a primary outcome measure in clinical trials.
NEUROPSYCHIATRIC ASSESSMENTS
Neuropsychiatric symptoms are common in mild to moderate AD, but in the clinical trial context, behavioral outcomes have generally served as secondary outcomes, with some exceptions. The Neuropsychiatric Inventory (NPI) 35 has become the standard instrument used in AD clinical trials. There are 2 key issues that distinguish neuropsychiatric symptoms from cognitive deficits in mild to moderate AD. First, in the mild to moderate AD patients who enroll in clinical trials, the burden of prevalent neuropsychiatric symptoms (ie, symptoms recorded at the time of enrollment) is modest. Second, the rate of treatment-emergent neuropsychiatric symptoms is also modest. To take 2 examples, a clinical trial of nonsteroidal anti-inflammatory agents in mild to moderate AD (MMSE 20.8 ± 3.6) noted that the baseline NPI score was 8.7 ± 10.6 and a 1-year decline of 3.4 ± 11.9 points, 20 whereas a trial of memantine in mild to moderate AD (MMSE 17.2 ± 3.4) found that the placebo group had a baseline score of 12.2 ± 13.0 and a 24-week decline of 0.9 ± 16.33 points. 36 In contrast, in a clinical trial specifically designed to test the antipsychotic agents in AD (MMSE score of 14.7 ± 5.8), the baseline NPI score in the placebo group was 39.1 ± 17.8 points. 37 Thus, at least in the clinical trials where AD patients were recruited for suitability to examine cognitive outcomes, the level of neuropsychiatric symptoms was far less than seen in patients recruited specifically because they had neuropsychiatric problems. These examples illustrate 2 additional points about neuropsychiatric symptoms in AD patients. There is a very substantial variability in the burden of neuropsychiatric symptoms. In addition, NPI scores rise with increasing baseline dementia severity.
DISEASE MODIFICATION VERSUS SYMPTOMATIC THERAPY
All stakeholders-patients, family members, physicians, insurers-in the field of AD therapeutics wish to have more potent medications, and it seems logical that treatments that get at the basic mechanisms of the disease would be more effective than those treatments that ameliorate a neurotransmitter deficit, for example, but do not alter the basic biologic tempo of the disease. Disease-modifying therapies are therefore the goal for AD therapeutics, where disease modification refers to slowing or aborting processes that are in the direct pathogenic pathway of the disease.
Proving that a therapy is disease-modifying turns out to be very difficult. A number of articles in the journal, Alzheimer's & Dementia in July 2006 extensively discussed the issues. It is difficult to summarize briefly, but there are analytic strategies using data from cognitive assessment that can, in principle, be used to claim that a treatment is disease modifying. The goal when using cognitive test data to support the idea of disease modification is to show a divergence in the rate of decline in the slope of the cognitive test score curves between study drug and control group. Unfortunately slope analysis is analytically challenging. For example, as previously mentioned, many trials have observed that both the placebo and drug treated show improvements on the ADAScog after 6 and sometimes 12 weeks of therapy. Thereafter, scores decline. Such a nonlinear pattern of performance is not well suited for analyses such as slope that assume linearity. Certain designs have also been proposed to test for disease modification. The randomized start and a randomized withdrawal approaches were formulated to demonstrate the divergence of cognition and global ratings 38 over the course of the trial, but there are many vexing conceptual issues with both of those designs, that discourage their use. 39 Just like cross-over designs, both of these approaches are compromised by the fact that the deficits in AD are not static, but instead worsen over time.
The idea that biomarkers can also support a diseasemodifying claim is viewed as having great potential. Support for disease modification by neuroimaging evidence has been sought for several years, but so far the trials in which imaging was used 40, 41 failed to find drug benefits. Although there are several candidate biomarkers such as structural imaging with magnetic resonance, functional imaging with positron emission tomography and cerebrospinal fluid markers, none have had the good fortune to be included in a clinical trial that showed clear clinical improvements with treatment. Thus, it remains unknown whether biomarkers are capable of showing changes in the direction of improvement that paralleled clinical improvement.
SUMMARY
Therapeutic trial methodology for mild to moderate AD has become much more sophisticated in the past 20 years, but many challenges remain for improvement in the efficiency of getting compounds from an interesting phase 2 profile to demonstration of efficacy of a drug in a phase 3 trial. Trial design issues should not impede progress and should not act as a barrier to test new drugs. As the field moves toward treatment of yet milder patients including those with mild cognitive impairment, the lessons learned with mild to moderate AD will be invaluable.
